$102 Million is the total value of Burrage Capital Management LLC's 31 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 112.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRNX | Buy | CRINETICS PHARMACEUTICALS INC | $4,022,000 | -22.1% | 282,272 | +37.2% | 3.96% | +14.4% |
| CYTK | New | CYTOKINETICS INC | $3,614,000 | – | 318,273 | +100.0% | 3.56% | – |
| RGNX | New | REGENXBIO INC | $3,537,000 | – | 115,000 | +100.0% | 3.48% | – |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $3,463,000 | -12.5% | 482,982 | +1.4% | 3.41% | +28.6% |
| AVRO | New | AVROBIO INC | $3,273,000 | – | 225,900 | +100.0% | 3.22% | – |
| TPTX | New | TURNING PT THERAPEUTICS INC | $3,250,000 | – | 77,172 | +100.0% | 3.20% | – |
| FREQ | Buy | FREQUENCY THERAPEUTICS INC | $3,009,000 | +220.8% | 173,917 | +225.0% | 2.96% | +370.7% |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $2,901,000 | +13.1% | 196,438 | +55.2% | 2.86% | +66.2% |
| TCDA | Buy | TRICIDA INC | $2,782,000 | +4.4% | 131,661 | +86.3% | 2.74% | +53.2% |
| XENE | New | XENON PHARMACEUTICALS INC | $2,112,000 | – | 200,000 | +100.0% | 2.08% | – |
| ZGNX | New | ZOGENIX INC | $1,652,000 | – | 70,000 | +100.0% | 1.63% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $1,609,000 | – | 112,546 | +100.0% | 1.58% | – |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $1,559,000 | +326.0% | 156,012 | +390.6% | 1.53% | +526.1% |
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $1,167,000 | – | 115,899 | +100.0% | 1.15% | – |
| INSM | New | INSMED INC | $1,007,000 | – | 65,400 | +100.0% | 0.99% | – |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $280,000 | +51.4% | 682,586 | +24.5% | 0.28% | +122.6% |
| AUTL | Buy | AUTOLUS THERAPEUTICS LTDspon ads | $84,000 | -51.4% | 15,006 | +14.4% | 0.08% | -28.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EPIZYME INC COM | 7 | Q2 2021 | 15.9% |
| NeoGenomics Inc | 7 | Q2 2021 | 8.7% |
| OrthoPediatrics Corp | 7 | Q2 2021 | 7.3% |
| Y-MABS THERAPEUTICS INC COM | 7 | Q2 2021 | 4.3% |
| CRINETICS PHARMACEUTICALS INC COM | 7 | Q2 2021 | 5.6% |
| G1 THERAPEUTICS INC COM | 7 | Q2 2021 | 7.3% |
| PTC THERAPEUTICS INC COM | 6 | Q1 2021 | 8.0% |
| CYTOKINETICS INC COM NEW | 6 | Q2 2021 | 4.9% |
| TURNING PT THERAPEUTICS INC COM | 6 | Q2 2021 | 6.7% |
| APELLIS PHARMACEUTICALS INC COM | 6 | Q1 2021 | 3.5% |
View Burrage Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.Sold out | July 30, 2021 | 0 | 0.0% |
| IVERIC bio, Inc. | February 14, 2020 | 10 | 3.4% |
View Burrage Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2021-07-30 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-12 |
| SC 13G | 2021-02-12 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
View Burrage Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.